Eli Lilly Earnings Call Recap: Retatrutide News
Summary
Host Dave Knapp analyzes Eli Lilly’s Q2 2026 earnings, focusing on the company’s push to classify retatrutide as a biologic to protect market dominance. He discusses the ongoing FDA litigation, strong Zetbound sales, and the lagging performance of oral semaglutide compared to injectables. The episode also covers emerging drugs like allurilintide and brinipatide, highlighting their potential for treating obesity and other conditions.
Topics discussed
Intro: Q2 2026 Eli Lilly Earnings Call Overview
Retatrutide Biologic Status and FDA Litigation
BLA Submission Strategy and Lack of Plan B
Investor Confidence and Biosimilar Implications
Foundeo vs. Wegovy Pill: Efficacy and Adoption
Gray Market Impact and Retatrutide Side Effects
Next-Gen Drugs: Brinzipetide and Clinical Trials
Q2 Financials: $14.9B Sales and Market Growth
Lilly Stock Outlook and Non-GLP-1 Business
Allura Lintide: Pricing, Gray Market, and Trials
Viewer Spotlight: Jay's Weight Loss Journey
Community Updates: Newsletter and New Studio Plans
Host's Personal Journey and Podcast Promotion
Listen ad-free on Castria